Welcome to our dedicated page for Theratechnologies Common news (Ticker: THTX), a resource for investors and traders seeking the latest updates and insights on Theratechnologies Common stock.
Theratechnologies Inc. (symbol: THTX) is a biopharmaceutical company that markets prescription products across the United States, Europe, and Canada. Founded in 1993 and headquartered in Montreal, Canada, the company is dedicated to addressing the unmet medical needs of patients living with HIV and other serious health conditions.
Core Products:
- EGRIFTA and EGRIFTA SV: These products help reduce excess abdominal fat in HIV-infected patients with lipodystrophy, improving their quality of life.
- Trogarzo: A vital injection treatment for multidrug-resistant HIV-1 infected patients, offering hope to those who have limited treatment options.
Pipeline Products:
- F8 Formulation: A promising treatment for HIV-associated lipodystrophy, currently in development.
- TH-1902: A potential breakthrough in the treatment of triple-negative breast cancer.
- TH-1904: Targeting ovarian cancer, another pipeline product with significant potential.
Theratechnologies generates significant revenue from its relationship with RxCrossroads, a major customer based in the United States. The company's strategic partnerships and innovative products showcase its commitment to improving patient outcomes in serious medical conditions. With a dedicated focus on research and development, Theratechnologies continues to make strides in the biopharmaceutical industry.
Rhea-AI Summary
Theratechnologies Inc. has closed its previously announced public offering, raising gross proceeds of US$12.5 million. The offering consisted of 12.5 million common shares at a price of US$1.00 per share. The underwriter has been granted a 30-day option to purchase an additional 1.875 million common shares. The company also closed a concurrent private placement with Investissement Québec, resulting in aggregate gross proceeds of US$12.5 million. Investissement Québec now beneficially owns approximately 19.9% of the issued and outstanding common shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.17%
Tags
-
Rhea-AI Summary
Theratechnologies Inc. has priced its public offering of 12,500,000 common shares at a price of US$1.00 per share, with expected gross proceeds of approximately US$12,500,000. The company has also granted the underwriter a 30-day option to purchase up to 1,875,000 common shares at the offering price. A concurrent private placement with Investissement Québec for 9,118,184 common shares and exchangeable subscription receipts is also part of the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-28.13%
Tags
-
Rhea-AI Summary
Theratechnologies Inc. has announced the launch of a marketed public offering of common shares, as well as a concurrent private placement with Investissement Québec. The underwriter has been granted an option to purchase additional shares. The consummation of the private placement is contingent upon the closing of the public offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-28.13%
Tags
Rhea-AI Summary
Theratechnologies Inc. announces changes to its operations, including a reduction of up to 25 positions. The company expects to save approximately US$3.5 million per year and record a restructuring charge of approximately US$1.5 million in Q4 2023. Clinical research activities in oncology and NASH will be made through partnership deals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.95%
Tags
-
Rhea-AI Summary
Theratechnologies shares data on the cost-effectiveness of ibalizumab for heavily treatment-experienced people with HIV
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.24%
Tags
-
Rhea-AI Summary
Theratechnologies presents data demonstrating that treatment with tesamorelin reduces visceral adipose tissue (VAT) and hepatic fat fraction (HFF) in people with HIV on integrase inhibitor-based regimens.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.76%
Tags
Rhea-AI Summary
Theratechnologies announces results from TMB-302 study on Trogarzo® administration
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.76%
Tags
-
Rhea-AI Summary
Theratechnologies announces dosing of the first participant in Phase 1 clinical trial of sudocetaxel zendusortide in ovarian cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.69%
Tags
-
Rhea-AI Summary
Theratechnologies announces FDA's assigned goal date for the approval of tesamorelin's F8 formulation
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
Rhea-AI Summary
Theratechnologies reported Q3 2023 consolidated revenue of $20.9 million and adjusted EBITDA of $2.2 million. They submitted the BLA for the F8 formulation of tesamorelin to the FDA. They also reached an agreement in principle on key amendments to their loan facility with Marathon. Revenue growth potential expected from the F8 formulation. Tightened FY2023 revenue guidance to $82-85 million, representing 3-6% growth. Net sales of EGRIFTA SV increased by 2.4% in Q3 2023, while Trogarzo net sales decreased by 3.3%. R&D expenses decreased by 36% in Q3 2023. Selling expenses decreased compared to last year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.27%
Tags
FAQ
What is the current stock price of Theratechnologies Common (THTX)?
The current stock price of Theratechnologies Common (THTX) is $1.8262 as of December 24, 2024.
What is the market cap of Theratechnologies Common (THTX)?
The market cap of Theratechnologies Common (THTX) is approximately 84.0M.
What does Theratechnologies Inc. specialize in?
Theratechnologies Inc. specializes in biopharmaceutical solutions for HIV and serious medical conditions like cancer.
Where are Theratechnologies' products marketed?
Theratechnologies markets its products in the United States, Europe, and Canada.
What are the main products offered by Theratechnologies?
The main products include EGRIFTA and EGRIFTA SV for HIV-related lipodystrophy and Trogarzo for multidrug-resistant HIV-1.
What are Theratechnologies' pipeline products?
Pipeline products include the F8 formulation for HIV-associated lipodystrophy, TH-1902 for triple-negative breast cancer, and TH-1904 for ovarian cancer.
When was Theratechnologies Inc. founded?
Theratechnologies Inc. was founded in 1993.
Where is Theratechnologies Inc. headquartered?
Theratechnologies Inc. is headquartered in Montreal, Canada.
Who is a major customer of Theratechnologies?
RxCrossroads, based in the United States, is a major customer of Theratechnologies.
What is the significance of Trogarzo?
Trogarzo is an important treatment for patients with multidrug-resistant HIV-1, providing a crucial option for those with limited alternatives.
How does EGRIFTA benefit HIV patients?
EGRIFTA helps reduce excess abdominal fat in HIV-infected patients with lipodystrophy, improving their health and quality of life.
What is Theratechnologies' approach to innovation?
Theratechnologies focuses on research and development to create innovative treatments for serious medical conditions and improve patient outcomes.
Theratechnologies Inc. Common